share_log

Eyenovia Analyst Ratings

Eyenovia Analyst Ratings

Eyenovia 分析師評級
Benzinga ·  2023/11/14 19:38
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
11/14/2023 875.61% HC Wainwright & Co. → $12 Reiterates Buy → Buy
11/01/2023 William Blair Initiates Coverage On → Outperform
10/17/2023 550.41% Brookline Capital → $8 Initiates Coverage On → Buy
08/18/2023 875.61% HC Wainwright & Co. → $12 Reiterates Buy → Buy
08/11/2023 875.61% HC Wainwright & Co. → $12 Reiterates Buy → Buy
05/12/2023 875.61% HC Wainwright & Co. → $12 Reiterates Buy → Buy
04/19/2023 875.61% HC Wainwright & Co. → $12 Reiterates → Buy
04/03/2023 875.61% HC Wainwright & Co. → $12 Reiterates → Buy
10/05/2022 875.61% HC Wainwright & Co. → $12 Initiates Coverage On → Buy
04/01/2021 550.41% HC Wainwright & Co. $6 → $8 Maintains Buy
10/23/2020 387.8% HC Wainwright & Co. $7 → $6 Maintains Buy
10/14/2020 794.31% Roth Capital $14 → $11 Maintains Buy
08/13/2020 469.11% HC Wainwright & Co. $6 → $7 Maintains Buy
03/26/2020 387.8% HC Wainwright & Co. $10 → $6 Reiterates Buy → Buy
02/03/2020 Oppenheimer Downgrades Outperform → Perform
04/25/2019 631.71% Oppenheimer → $9 Initiates Coverage On → Outperform
日期 上行/下行 分析公司 目標價格變動 評級變動 之前/當前的評級
11/14/2023 875.61% HC Wainwright & Co. → 12 美元 重申 購買 → 購買
11/01/2023 威廉布萊爾 啓動覆蓋範圍開啓 → 跑贏大盤
10/17/2023 550.41% 布魯克林資本 → 8 美元 啓動覆蓋範圍開啓 → 購買
08/18/2023 875.61% HC Wainwright & Co. → 12 美元 重申 購買 → 購買
08/11/2023 875.61% HC Wainwright & Co. → 12 美元 重申 購買 → 購買
05/12/2023 875.61% HC Wainwright & Co. → 12 美元 重申 購買 → 購買
04/19/2023 875.61% HC Wainwright & Co. → 12 美元 重申 → 購買
04/03/2023 875.61% HC Wainwright & Co. → 12 美元 重申 → 購買
2022年5月10日 875.61% HC Wainwright & Co. → 12 美元 啓動覆蓋範圍開啓 → 購買
2021 年 1 月 4 日 550.41% HC Wainwright & Co. 6 美元 → 8 美元 維護
2020 年 10 月 23 日 387.8% HC Wainwright & Co. 7 美元 → 6 美元 維護
2020 年 10 月 14 日 794.31% 羅斯資本 14 美元 → 11 美元 維護
08/13/2020 469.11% HC Wainwright & Co. 6 美元 → 7 美元 維護
2020 年 3 月 26 日 387.8% HC Wainwright & Co. 10 美元 → 6 美元 重申 購買 → 購買
2020 年 3 月 2 日 奧本海默 降級 跑贏大盤 → 表現
04/25/2019 631.71% 奧本海默 → 9 美元 啓動覆蓋範圍開啓 → 跑贏大盤

What is the target price for Eyenovia (EYEN)?

Eyenovia (EYEN) 的目標價格是多少?

The latest price target for Eyenovia (NASDAQ: EYEN) was reported by HC Wainwright & Co. on November 14, 2023. The analyst firm set a price target for $12.00 expecting EYEN to rise to within 12 months (a possible 875.61% upside). 8 analyst firms have reported ratings in the last year.

HC Wainwright & Co. 於2023年11月14日公佈了Eyenovia(納斯達克股票代碼:EYEN)的最新目標股價。該分析公司將目標股價定爲12.00美元,預計EYEN將在12個月內升至12個月內(可能上漲875.61%)。去年有8家分析公司公佈了評級。

What is the most recent analyst rating for Eyenovia (EYEN)?

分析師對Eyenovia (EYEN) 的最新評級是多少?

The latest analyst rating for Eyenovia (NASDAQ: EYEN) was provided by HC Wainwright & Co., and Eyenovia reiterated their buy rating.

Eyenovia(納斯達克股票代碼:EYEN)的最新分析師評級由HC Wainwright & Co. 提供,Eyenovia重申了他們的買入評級。

When is the next analyst rating going to be posted or updated for Eyenovia (EYEN)?

Eyenovia(EYEN)的下一個分析師評級何時公佈或更新?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Eyenovia, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Eyenovia was filed on November 14, 2023 so you should expect the next rating to be made available sometime around November 14, 2024.

分析師在進行了廣泛的研究後得出了股票評級,其中包括瀏覽公開財務報表、與Eyenovia的高管和客戶交談以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級,因此每家公司每年應該獲得4次評級。Eyenovia的最新評級是在2023年11月14日發佈的,因此您應該預計下一個評級將在2024年11月14日左右公佈。

Is the Analyst Rating Eyenovia (EYEN) correct?

分析師對Eyenovia (EYEN) 的評級正確嗎?

While ratings are subjective and will change, the latest Eyenovia (EYEN) rating was a reiterated with a price target of $0.00 to $12.00. The current price Eyenovia (EYEN) is trading at is $1.23, which is within the analyst's predicted range.

儘管評級是主觀的,並且會發生變化,但重申了最新的Eyenovia(EYEN)評級,目標股價爲0.00美元至12.00美元。Eyenovia(EYEN)目前的交易價格爲1.23美元,在分析師的預測區間內。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論